ADC · c-Met

2개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2 programs
ADCCurated CoreFDAAbbVieMMAE (microtubule inhibitor)Approved

telisotuzumab vedotin (Emrelis, ABBV-399, Teliso-V, telisotuzumab-vedotin-tllv)

Previously treated locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression · c-Met

#c-Met#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 12Status Approved
ADCLimited DatastaleAbbViePhase 2

Telisotuzumab Adizutecan (Telisotuzumab Adizutecan)

Metastatic Colorectal Cancer · Non Small Cell Lung Carcinoma

#NonSmallCellLungCarcinoma#ADC#Phase2#antibody-drug-conjugate#MetastaticColorectalCancer+1
Trials 13Status Recruiting